Biodesix Inc stock surges amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 01 2026
0mins
Should l Buy BDSX?
Source: Coinmarketcap
Biodesix Inc's stock price has surged by 34.43% in pre-market trading, crossing above its 5-day SMA, despite the broader market downturn with the Nasdaq-100 down 0.76% and the S&P 500 down 0.58%.
The significant price increase appears to be driven by a recent announcement regarding a new diagnostic test that Biodesix has developed, which is expected to enhance its market position. This development has generated positive investor sentiment, leading to increased buying activity in the stock.
This surge in Biodesix's stock could indicate a strong market interest in its innovative solutions, potentially positioning the company for future growth despite the overall market weakness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDSX
Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is 30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.960
Low
20.00
Averages
30.00
High
40.00
Current: 9.960
Low
20.00
Averages
30.00
High
40.00
About BDSX
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Friedland Enterprises Acquires 5% Stake in Lulu's Fashion Lounge
- Share Acquisition: Friedland Enterprises announced the acquisition of approximately 5% of the outstanding shares of Lulu's Fashion Lounge, aiming to enhance its market influence in the fashion retail sector and potentially provide greater strategic flexibility.
- Market Signal: This acquisition indicates Friedland's confidence in Lulu's future growth potential, which may attract other investors' attention, thereby increasing Lulu's market valuation and investment appeal.
- Investment Strategy: By increasing its stake, Friedland plans to exert greater influence over Lulu's decision-making, driving business development and brand strategy, further solidifying its position in the competitive fashion industry.
- Industry Consolidation: This transaction may signal a trend of consolidation in the fashion retail sector, with Friedland's move potentially inspiring other investors to pursue similar acquisitions to seek higher market share and synergies.
See More
Biodesix (BDSX) Q4 and FY2025 Outlook Exceeds Estimates with $28.8M Revenue
- Significant Revenue Growth: Biodesix expects FY2025 revenue of $88.5 million, a 24% YoY increase, surpassing the analyst consensus estimate of $84.65 million, indicating strong performance in the lung diagnostics sector.
- Increased Test Volumes: Test volumes reached 18,000 in Q4 and 62,600 for the year, reflecting a 23% and 15% YoY increase, respectively, showcasing the company's enhanced market demand and service capabilities.
- Lung Diagnostics Contribution: The lung diagnostics segment contributed $25.2 million in Q4 and $79.2 million for the full year, representing YoY growth of 47% and 22%, highlighting the strong growth potential of this division.
- Robust Cash Flow: Biodesix ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase from the previous quarter, providing solid financial support for future growth.
See More
NASDAQ 100 Pre-Market Indicator Drops 170.91 Points
- Market Dynamics: The NASDAQ 100 Pre-Market Indicator has dropped by 170.91 points to 25,595.35, indicating a weak market sentiment that may impact investor confidence.
- Active Stocks: Biodesix, Inc. (BDSX) rose by 1.2 to $6.66 with a trading volume of 10,058,408 shares, reflecting a positive market response to its buy recommendation.
- Price Fluctuations: Direxion Daily TSLA Bull 2X Shares (TSLL) fell by 0.3102 to $18.26 with a volume of 4,966,541 shares, representing a 190.3% increase from its 52-week low, highlighting strong market interest in Tesla.
- Target Price Proximity: Novo Nordisk A/S (NVO) increased by 1.1 to $59.91 with 817,870 shares traded, currently at 112.3% of its target price of $53.35, indicating optimistic market expectations for its future performance.
See More
Biodesix (BDSX) Reports 22% Revenue Growth for 2025, Stock Surges 31.87%
- Significant Revenue Growth: Biodesix's estimated full-year revenue for 2025 is $88.5 million, a 24% increase from $71.3 million last year, exceeding the updated guidance range of $84-$86 million announced on November 3, indicating strong market performance.
- Impressive Q4 Results: The estimated revenue for the fourth quarter is $28.8 million, up 41% from $20.4 million in the same quarter last year, with Lung Diagnostics revenue reaching $25.2 million, a 47% increase, reflecting growth in test volumes and higher average revenue per test.
- Positive Adjusted EBITDA: The company affirmed a positive Adjusted EBITDA compared to a loss of $3.9 million in the same quarter last year, indicating significant progress in cost control and operational efficiency, enhancing confidence in future profitability.
- Positive Stock Reaction: Following the earnings report, BDSX's stock surged 31.87% in pre-market trading to $7.21, reflecting investor optimism regarding the company's growth potential.
See More
Biodesix Reports $88.5M Revenue for 2025, Up 24%
- Significant Revenue Growth: Biodesix anticipates total revenue of $88.5 million for 2025, representing a 24% increase, exceeding the upper limit of the company's revised guidance, indicating strong performance in the lung diagnostics sector.
- Lung Diagnostics Revenue Surge: The estimated lung diagnostics revenue for 2025 is $79.2 million, up 22% year-over-year, with Q4 revenue at $25.2 million, reflecting a 47% increase driven by higher test volumes and expanded reimbursement.
- Strong Cash Position: As of December 31, 2025, Biodesix reported cash and cash equivalents of $19.0 million, a 14% increase from Q3 2025, providing a solid financial foundation for future operations and investments.
- Positive Adjusted EBITDA Outlook: The company affirms expectations of positive Adjusted EBITDA for Q4 2025, indicating improving profitability supported by sustained revenue growth and operational leverage.
See More
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.
See More
Friedland Enterprises Acquires 5% Stake in Lulu's Fashion Lounge
- Share Acquisition: Friedland Enterprises announced the acquisition of approximately 5% of the outstanding shares of Lulu's Fashion Lounge, aiming to enhance its market influence in the fashion retail sector and potentially provide greater strategic flexibility.
- Market Signal: This acquisition indicates Friedland's confidence in Lulu's future growth potential, which may attract other investors' attention, thereby increasing Lulu's market valuation and investment appeal.
- Investment Strategy: By increasing its stake, Friedland plans to exert greater influence over Lulu's decision-making, driving business development and brand strategy, further solidifying its position in the competitive fashion industry.
- Industry Consolidation: This transaction may signal a trend of consolidation in the fashion retail sector, with Friedland's move potentially inspiring other investors to pursue similar acquisitions to seek higher market share and synergies.
See More
Biodesix (BDSX) Q4 and FY2025 Outlook Exceeds Estimates with $28.8M Revenue
- Significant Revenue Growth: Biodesix expects FY2025 revenue of $88.5 million, a 24% YoY increase, surpassing the analyst consensus estimate of $84.65 million, indicating strong performance in the lung diagnostics sector.
- Increased Test Volumes: Test volumes reached 18,000 in Q4 and 62,600 for the year, reflecting a 23% and 15% YoY increase, respectively, showcasing the company's enhanced market demand and service capabilities.
- Lung Diagnostics Contribution: The lung diagnostics segment contributed $25.2 million in Q4 and $79.2 million for the full year, representing YoY growth of 47% and 22%, highlighting the strong growth potential of this division.
- Robust Cash Flow: Biodesix ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase from the previous quarter, providing solid financial support for future growth.
See More
NASDAQ 100 Pre-Market Indicator Drops 170.91 Points
- Market Dynamics: The NASDAQ 100 Pre-Market Indicator has dropped by 170.91 points to 25,595.35, indicating a weak market sentiment that may impact investor confidence.
- Active Stocks: Biodesix, Inc. (BDSX) rose by 1.2 to $6.66 with a trading volume of 10,058,408 shares, reflecting a positive market response to its buy recommendation.
- Price Fluctuations: Direxion Daily TSLA Bull 2X Shares (TSLL) fell by 0.3102 to $18.26 with a volume of 4,966,541 shares, representing a 190.3% increase from its 52-week low, highlighting strong market interest in Tesla.
- Target Price Proximity: Novo Nordisk A/S (NVO) increased by 1.1 to $59.91 with 817,870 shares traded, currently at 112.3% of its target price of $53.35, indicating optimistic market expectations for its future performance.
See More
Biodesix (BDSX) Reports 22% Revenue Growth for 2025, Stock Surges 31.87%
- Significant Revenue Growth: Biodesix's estimated full-year revenue for 2025 is $88.5 million, a 24% increase from $71.3 million last year, exceeding the updated guidance range of $84-$86 million announced on November 3, indicating strong market performance.
- Impressive Q4 Results: The estimated revenue for the fourth quarter is $28.8 million, up 41% from $20.4 million in the same quarter last year, with Lung Diagnostics revenue reaching $25.2 million, a 47% increase, reflecting growth in test volumes and higher average revenue per test.
- Positive Adjusted EBITDA: The company affirmed a positive Adjusted EBITDA compared to a loss of $3.9 million in the same quarter last year, indicating significant progress in cost control and operational efficiency, enhancing confidence in future profitability.
- Positive Stock Reaction: Following the earnings report, BDSX's stock surged 31.87% in pre-market trading to $7.21, reflecting investor optimism regarding the company's growth potential.
See More
Biodesix Reports $88.5M Revenue for 2025, Up 24%
- Significant Revenue Growth: Biodesix anticipates total revenue of $88.5 million for 2025, representing a 24% increase, exceeding the upper limit of the company's revised guidance, indicating strong performance in the lung diagnostics sector.
- Lung Diagnostics Revenue Surge: The estimated lung diagnostics revenue for 2025 is $79.2 million, up 22% year-over-year, with Q4 revenue at $25.2 million, reflecting a 47% increase driven by higher test volumes and expanded reimbursement.
- Strong Cash Position: As of December 31, 2025, Biodesix reported cash and cash equivalents of $19.0 million, a 14% increase from Q3 2025, providing a solid financial foundation for future operations and investments.
- Positive Adjusted EBITDA Outlook: The company affirms expectations of positive Adjusted EBITDA for Q4 2025, indicating improving profitability supported by sustained revenue growth and operational leverage.
See More
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.
See More
